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Endobronchial valves in a highly parsed emphysema population
Lung volume reduction surgery is a thoracic surgical 
procedure whereby the hyperexpanded lungs of patients 
with severe emphysema are reduced in size by surgical 
excision of, ideally, the areas that are most severely 
destroyed.1,2 This operation, usually done bilaterally 
and almost always by video-assisted thoracoscopy, 
substantially improves pulmonary function, dyspnoea, 
and quality of life in appropriately selected patients. 
Several clinical series show about a 50% mean 
improvement in forced expiratory volume in 1 s (FEV1),3 
and increased survival has been shown in one subgroup 
of patients.4 Lung volume reduction surgery is among 
the most carefully studied operations in medicine, 
having been subjected to many randomised controlled 
trials, all of which established its eﬀ ectiveness.4–8
However, as with all operations, lung volume reduction 
surgery engenders some risk. To receive the beneﬁ ts, 
even appropriate candidates for lung volume reduction 
surgery must accept a 3–4% risk of perioperative death,4 
a 1–2 week hospitalisation, and a several week period of 
recovery. Thus, there has been an eﬀ ort to try to reduce 
the risk of lung volume reduction surgery and achieve the 
same physiological beneﬁ ts by less invasive approaches.
The best studied non-surgical approach to lung 
volume reduction is bronchoscopic placement of one-
way endobronchial valves (bronchoscopic lung volume 
reduction) designed to shut down air inﬂ ow to a segment 
or lobe, thereby allowing that region to collapse. 
Randomised studies with these valves, however, have 
shown very disappointing mean group improvements in 
various measures of lung function. These studies showed 
statistically, but not clinically, signiﬁ cant changes when 
all patients were analysed.9–11 Post-hoc analyses have 
suggested, not surprisingly, that those with markedly 
heterogeneous disease and complete interlobar ﬁ ssures 
(which do not allow collateral ventilation across them) 
improve more with valves than do other patients.11
In The Lancet, Claire Davey and colleagues12 compare 
bronchoscopic lung volume reduction with sham 
bronchoscopy in a randomised trial comprising 
50 patients with heterogeneous emphysema and intact 
interlobar ﬁ ssures. The authors show convincingly that 
prospective selection of patients with heterogeneous 
disease and minimal collateral ventilation yields 
substantially greater improvements than treatment of 
those without these characteristics. Although the results 
are not quite as impressive as in the post-hoc analysis 
of Sciurba and colleagues’ study,11 the present trial does 
show a median 8·77% (IQR 2·27–35·85) improvement 
in FEV1 after unilateral valve placement, as well as 
signiﬁ cant improvements in exercise capacity (the 
higher mean improvement in FEV1 of 24·8% is skewed 
by a few high-responding outliers). Extrapolation, 
however unscientiﬁ c, to expect a nearly doubled eﬀ ect if 
bronchoscopic lung volume reduction is done bilaterally 
might achieve results that are perhaps half of what can 
be achieved by surgery (18% improvement in FEV1 with 
valves vs 30–50% with surgery).
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There are some real strengths to Davey and 
colleagues’ study.12 The design is impressive in its 
inclusion of sham bronchoscopy in the control group. 
Very few studies of invasive procedures in medicine 
have included an actual operated sham group. This 
truly double-masked design meets the most stringent 
deﬁ nition of a high quality clinical trial. It is also notable 
that the study was funded by the UK Medical Research 
Council rather than the commercial producer of the 
valve, eliminating the potential for commercial bias, 
which has been present in many previous studies of 
endobronchial valves, nearly entirely.
Some very important ﬁ ndings, however, deserve to 
be more clearly highlighted. First, Davey and colleagues’ 
study12 does not bear out the expectation that 
bronchoscopic lung volume reduction is substantially 
less morbid that surgical lung volume reduction. In 
fact, two (8%) of the patients in the bronchoscopic lung 
volume reduction group died after the procedure (vs 
none in the control group). This death rate is higher than 
the perioperative death rate in nearly all modern surgical 
series of bilateral surgical lung volume reduction surgery. 
Although not statistically diﬀ erent between groups, 
there was also an apparent increase in respiratory and 
infectious complications in the valve patients: two 
patients needed valve removal, four expectorated a 
valve, two had pneumonia (vs zero controls), and two 
suﬀ ered pneumothorax (vs one control). It might be 
that the better lobar isolation achieved in these patients 
with intact ﬁ ssures led to more trouble as well as more 
beneﬁ t. These problems could explain why, despite 
the improvements in FEV1, the St George’s Respiratory 
Questionnaire scores were no better in treated patients 
than in controls.
Worse, would the rates of each of these problems be 
doubled if the bronchoscopic lung volume reduction 
procedure was done bilaterally, as would probably be 
needed for improvements after the procedure to reach 
the same ballpark as surgical results? Doubling an 8% 
mortality reaches a higher death rate than has been seen 
in any published series of surgical lung volume reduction 
other than the publication that deﬁ ned the high-risk 
subgroup within the NETT trial13—a group which now 
never undergoes the operation.
Lung volume reduction surgery is supported by 
very strong evidence establishing dramatic beneﬁ ts 
in properly selected patients. The study by Davey 
and colleagues12 does suggest that bronchoscopic 
lung volume reduction might ultimately provide an 
alternative, albeit one which aﬀ ords a lesser degree of 
palliation than surgical lung volume reduction, in the 
few patients with intact interlobar ﬁ ssures. However, we 
must be careful not to let this ﬁ nding make us forget the 
great value of surgical lung volume reduction in patients 
both with and without intact ﬁ ssures. It seems clear that 
surgery achieves improvements that are substantially 
higher than bronchoscopic lung volume reduction 
will ever be able to achieve—even in the most ideal 
candidates for bronchoscopic lung volume reduction—
and surgery might not even be more morbid.
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